{"ticker": {"uuid": "57732479-d40f-4a64-b253-95c5385929e9", "symbol": "FRNM", "name": "Freenome, Inc. Common stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "charts": {"tiers": [{"count": 15, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 7, "label": "Market update"}, {"count": 5, "label": "Earnings"}, {"count": 2, "label": "Regulatory and legal"}, {"count": 1, "label": "Deals and strategy"}], "sources": [{"label": "Stock Titan", "count": 5}, {"label": "Market source", "count": 2}, {"label": "MarketBeat", "count": 1}, {"label": "Investing.com Canada", "count": 1}, {"label": "Revelio Labs", "count": 1}, {"label": "Quiver Quantitative", "count": 1}, {"label": "Simply Wall Street", "count": 1}, {"label": "BioSpace", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "50/100"}, {"text": "1.01 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "15/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "76/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Market update"}, {"text": "78% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "15"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "1/100"}, {"text": "+3.7% over one week, - over four weeks, trend inactive, and near fair-value range.", "tone": "negative", "label": "Trend context", "value": "Trend inactive"}, {"text": "Freenome (FRNM) 10K Form and Latest SEC Filings 2026", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 7, "event": "general", "label": "Market update", "weight": 4.28}, {"count": 5, "event": "earnings", "label": "Earnings", "weight": 3.17}, {"count": 2, "event": "regulatory", "label": "Regulatory and legal", "weight": 1.15}, {"count": 1, "event": "deals", "label": "Deals and strategy", "weight": 0.6}], "pipeline": {"eodhd": {"status": "healthy", "calls_used": 1345, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 10000, "requests_made": 269, "newest_seen_at": "2026-08-15T21:50:19+00:00", "rate_remaining": 1199, "budget_used_pct": 13.5, "last_success_at": "2026-08-15T22:11:10.128864+00:00", "mapped_mentions": 4084, "unmapped_mentions": 2458}, "status": "partial", "raw_articles": 42, "eodhd_articles": 0, "unique_stories": 24, "direct_evidence": 15, "provider_counts": {"eodhd": 0, "google_news": 14, "alphavantage": 14}, "provider_errors": {}, "archive_articles": 0, "current_evidence": 2, "relevant_stories": 15, "duplicates_removed": 18, "durable_story_count": 14, "providers_attempted": 3, "durable_collected_at": "2026-08-15T12:08:05.639194+00:00", "durable_evidence_used": true, "providers_with_results": 2, "matched_archive_stories": 15, "provider_rejected_counts": {"eodhd": 0, "google_news": 8, "alphavantage": 3}, "provider_relevant_counts": {"eodhd": 0, "google_news": 6, "alphavantage": 11}, "durable_newest_article_at": "2026-08-13T21:41:10+00:00"}, "confidence": 76, "primary_event": "general", "primary_label": "Market update", "negative_events": 0, "positive_events": 2}, "updated_at": "2026-08-15T22:14:42.210291+00:00", "total_unique": 15, "total_fetched": 15, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 15, "event_label": "Market update", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "negative", "latest_week": "2026-08-14", "trend_label": "Trend inactive", "latest_close": 11.56, "trend_signal": "0", "one_week_move": 3.7, "reaction_tone": "positive", "fair_value_gap": 2.5, "four_week_move": null, "reaction_label": "Price confirming higher", "fair_value_tone": "neutral", "market_dynamics": 0.0, "market_sentence": "+3.7% over one week, - over four weeks, trend inactive, and near fair-value range.", "fair_value_label": "Near fair-value range", "twelve_week_move": null, "relative_strength": null, "has_market_context": true, "expectation_direction": "negative", "expectation_probability": 0.0, "market_dynamics_buy_signal": false}, "total_relevant": 15, "pipeline_health": {"eodhd": {"status": "healthy", "calls_used": 1345, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 10000, "requests_made": 269, "newest_seen_at": "2026-08-15T21:50:19+00:00", "rate_remaining": 1199, "budget_used_pct": 13.5, "last_success_at": "2026-08-15T22:11:10.128864+00:00", "mapped_mentions": 4084, "unmapped_mentions": 2458}, "status": "partial", "raw_articles": 42, "eodhd_articles": 0, "unique_stories": 24, "direct_evidence": 15, "provider_counts": {"eodhd": 0, "google_news": 14, "alphavantage": 14}, "provider_errors": {}, "archive_articles": 0, "current_evidence": 2, "relevant_stories": 15, "duplicates_removed": 18, "durable_story_count": 15, "providers_attempted": 3, "durable_collected_at": "2026-08-15T22:14:42.210291+00:00", "durable_evidence_used": true, "providers_with_results": 2, "matched_archive_stories": 15, "provider_rejected_counts": {"eodhd": 0, "google_news": 8, "alphavantage": 3}, "provider_relevant_counts": {"eodhd": 0, "google_news": 6, "alphavantage": 11}, "durable_newest_article_at": "2026-08-15T14:10:13+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 50, "total": 15, "neutral": 13, "negative": 0, "positive": 2, "raw_score": 57, "confidence": 15, "dispersion": 1, "story_count": 15, "window_days": 30, "direct_share": 78, "source_count": 2, "score_version": "evidence-v10", "evidence_count": 2, "evidence_status": "provisional", "information_mass": 0.018, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-15T14:10:13+00:00", "direct_story_count": 15, "effective_articles": 1.01, "sector_story_count": 0, "direct_source_count": 2, "industry_story_count": 0, "source_concentration": 0.9887, "directional_story_count": 2}, "articles": [{"url": "https://www.marketbeat.com/stocks/NASDAQ/FRNM/sec-filings", "tier": "direct", "title": "Freenome (FRNM) 10K Form and Latest SEC Filings 2026", "topics": ["Earnings", "Finance", "Financial Markets"], "summary": "This article provides an overview of Freenome's (FRNM) SEC filings, highlighting that the company has submitted over 82 documents since 2024. It details various filing types like 10-K, 10-Q, 8-K, and Form 4, explaining their significance for investors. The most recent filing mentioned is a Form SCHEDULE 13G/A submitted on August 14, 2026.", "age_days": 0.3, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/stocks/NASDAQ/FRNM/sec-filings", "source_name": "MarketBeat", "published_at": "2026-08-15T14:10:13", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 95.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.091625, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "15 Aug 2026 14:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/FRNM/8-k-a-freenome-inc-amends-material-event-report-c407cead4760.html", "tier": "direct", "title": "Freenome (FRNM) posts $132.6M loss but raises $295.5M via SPAC and PIPE", "topics": ["Earnings", "Finance", "IPO", "Life Sciences", "Mergers And Acquisitions"], "summary": "Freenome Inc. reported a net loss of $132.6 million for the first half of 2026, widening from the previous year, and used $97.1 million in operating cash. Despite these losses and an accumulated deficit of $1.5 billion, the company secured $295.5 million in net proceeds from a SPAC business combination and PIPE financing. This capital, along with existing liquidity, is expected to fund operations for at least 12 months, supporting ongoing R&D and commercialization efforts, especially after the recent FDA approval of its SimpleScreen\u2122 CRC test.", "age_days": 2.0, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/FRNM/8-k-a-freenome-inc-amends-material-event-report-c407cead4760.html", "source_name": "Stock Titan", "published_at": "2026-08-13T21:41:10", "tone_signals": ["Fda Approval"], "company_focus": 0.78, "freshness_pct": 81.8, "sentiment_pct": 53, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.073973, "influence_label": "None", "event_confidence": 93, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "13 Aug 2026 21:41", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://ca.investing.com/news/stock-market-news/form-8k-freenome-inc-for-13-august-93CH-4799859", "tier": "direct", "title": "Form 8K Freenome Inc For: 13 August By Investing.com", "topics": ["Earnings", "Financial Markets"], "summary": "This article from Investing.com announces that Freenome Inc. filed a Form 8K for August 13. The content of the filing itself is not detailed, as the article primarily serves as a notification of the filing. It mentions the stock symbol FRNM and provides general market data and other news.", "age_days": 2.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://ca.investing.com/news/stock-market-news/form-8k-freenome-inc-for-13-august-93CH-4799859", "source_name": "Investing.com Canada", "published_at": "2026-08-13T21:38:49", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 75.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.099088, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 21:38", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/news/FRNM/fda-grants-breakthrough-device-designation-to-freenome-s-blood-based-2jjlbqwwrcx6.html", "tier": "direct", "title": "Freenome targets lung screening gap; only about 18% of U.S. adults recommended get screened", "topics": ["Earnings", "Life Sciences", "Technology"], "summary": "Freenome has received FDA Breakthrough Device Designation for its investigational SimpleScreen\u2122 Lung test, a blood-based screening tool for lung cancer. The test is designed for high-risk adults aged 50-80 with a significant smoking history who are not currently undergoing recommended screening, aiming to address the substantial screening gap where only about 18% of eligible U.S. adults get screened. While the designation accelerates the review process and is a positive step, the market reacted with a slight decline in FRNM stock, as the test remains investigational and not yet FDA approved for routine use.", "age_days": 3.4, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/news/FRNM/fda-grants-breakthrough-device-designation-to-freenome-s-blood-based-2jjlbqwwrcx6.html", "source_name": "Stock Titan", "published_at": "2026-08-12T13:40:37", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 71.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.071757, "influence_label": "None", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 13:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://au.finance.yahoo.com/quote/FRNM/sec-filing", "tier": "direct", "title": "Freenome, Inc. (FRNM) stock price, news, quote and history", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "This article provides an overview of Freenome, Inc. (FRNM) stock performance, including its current price, news, and historical data. It details the company's stock price movement, key financial metrics like trailing total returns against the S&P 500, and lists relevant market data. The content also includes a snapshot of market activity for various indices and commodities.", "age_days": 7.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://au.finance.yahoo.com/quote/FRNM/sec-filing", "source_name": "Market source", "published_at": "2026-08-08T05:10:58", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 34.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.025895, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Aug 2026 05:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.reveliolabs.com/companies/freenome-holdings/employees", "tier": "direct", "title": "Freenome Holdings Number of Employees 2026 | Employee Count & Headcount Data", "topics": ["Finance", "Life Sciences"], "summary": "Freenome Holdings, a Biotech and Healthcare Services company founded in 2014 and headquartered in Brisbane, California, had approximately 527 employees worldwide as of March 2026. This represents a 26.8% decline from 719 employees in 2023, though the company saw a slight increase from a low of 519 in Q4 2025. The workforce is concentrated in the United States (74.8%), with an average salary of $149,649, and the company is actively hiring with 42 job postings in 2026.", "age_days": 13.5, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.reveliolabs.com/companies/freenome-holdings/employees", "source_name": "Revelio Labs", "published_at": "2026-08-02T09:11:11", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 0.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000642, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "02 Aug 2026 09:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5JWm5ra05qZFc3R2kyVE13a1c0aWtWZ21lbVJIUWpHa1N4QkR2YVR4NGFkck5SU2FsZko2ODRxZmZlTTdleGRuWTZXb1FsZWxk?oc=5", "tier": "direct", "title": "FRNM | Freenome, Inc. Common stock Stock Data, Price & News", "topics": [], "summary": "", "age_days": 15.7, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5JWm5ra05qZFc3R2kyVE13a1c0aWtWZ21lbVJIUWpHa1N4QkR2YVR4NGFkck5SU2FsZko2ODRxZmZlTTdleGRuWTZXb1FsZWxk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-31T04:37:39+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000229, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Jul 2026 04:37", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-frnm/freenome/information", "tier": "direct", "title": "Freenome, Inc. (FRNM) Company Information", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences", "Technology"], "summary": "This article provides company information for Freenome, Inc. (FRNM), including its key details like ticker, exchange, founding year, industry, and market capitalization. It also outlines the data sources used for the company analysis, such as financial statements, analyst estimates, and market prices, and mentions that Freenome, Inc. is not covered by any analysts for revenue or earnings estimates.", "age_days": 18.9, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-frnm/freenome/information", "source_name": "Simply Wall Street", "published_at": "2026-07-28T01:40:36", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 7.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00703, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Jul 2026 01:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/freenome-secures-fda-nod-blood-153750014.html", "tier": "direct", "title": "Freenome secures FDA nod for blood-based colorectal cancer test", "topics": ["Life Sciences"], "summary": "Freenome has received FDA approval for its blood-based colorectal cancer screening test, SimpleScreen CRC. Abbott will exclusively market the test in the U.S., adding it to its existing portfolio which includes the Cologuard stool test. The test is approved for adults 45 and older at average risk for colorectal cancer and aims to address the significant number of unscreened individuals.", "age_days": 19.4, "is_stale": false, "sentiment": "positive", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/freenome-secures-fda-nod-blood-153750014.html", "source_name": "Market source", "published_at": "2026-07-27T11:41:10", "tone_signals": ["Fda Approval"], "company_focus": 0.78, "freshness_pct": 14.6, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 99.4, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.018151, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 34, "published_display": "27 Jul 2026 11:41", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "99.4"}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPWmJiLXVWQkhtMFF3OThrd2hpcTN1dVRjbEF0aW5GdE5XblpUeEFnZ3lOc1gyaGUycEJha1pDeVpsSFNycEM0NGZUcmpzOHpGYjRLeC01alJHWV9vRUtraVFDNFprcElIdVVYNU9PbWpNSmMzVFd4cTVSNWxOV09rc3AzM0hhdm9DZ013Ym5RdE94T2FHeFJWWFQ2VERCT0I5UUlGSWJ3X2R0cllLbXNGQ0RVMExIUFNnTXVFQWpFdDNmbkJhTDltODJSYw?oc=5", "tier": "direct", "title": "Freenome, Inc. (PCSC) CPO details common stock and multiple option grants", "topics": [], "summary": "", "age_days": 19.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPWmJiLXVWQkhtMFF3OThrd2hpcTN1dVRjbEF0aW5GdE5XblpUeEFnZ3lOc1gyaGUycEJha1pDeVpsSFNycEM0NGZUcmpzOHpGYjRLeC01alJHWV9vRUtraVFDNFprcElIdVVYNU9PbWpNSmMzVFd4cTVSNWxOV09rc3AzM0hhdm9DZ013Ym5RdE94T2FHeFJWWFQ2VERCT0I5UUlGSWJ3X2R0cllLbXNGQ0RVMExIUFNnTXVFQWpFdDNmbkJhTDltODJSYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 5.9e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNOWZzSHJvQkZYZkt0aGEzek1sWkQwUmp0UUJjeS1HaDF4WHJtakVVMlFPZm0wUXhXTkt1Rnhjd0hVSndERjNzWWh0NXJfcVZsemhZLXNxMWJFa0tEVmNjUkRJRkMyYlpSMXdQQWZzQUF4Z1dEM19OZTBiazFtUHg2SlpVNHpQY3RudE5iUngyazd3T3hybzloc1J0cUZmWEdmc0pSd3JSeURobjI5Y2pwZmstRHpTSXlCcW50N2dKZXEwSnE2cVJKLXZVUQ?oc=5", "tier": "direct", "title": "Freenome, Inc. (PCSC) director reports common stock and option stakes", "topics": [], "summary": "", "age_days": 19.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNOWZzSHJvQkZYZkt0aGEzek1sWkQwUmp0UUJjeS1HaDF4WHJtakVVMlFPZm0wUXhXTkt1Rnhjd0hVSndERjNzWWh0NXJfcVZsemhZLXNxMWJFa0tEVmNjUkRJRkMyYlpSMXdQQWZzQUF4Z1dEM19OZTBiazFtUHg2SlpVNHpQY3RudE5iUngyazd3T3hybzloc1J0cUZmWEdmc0pSd3JSeURobjI5Y2pwZmstRHpTSXlCcW50N2dKZXEwSnE2cVJKLXZVUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 5.9e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNdFNpVzZ0dC1yM2o3UjljSUo2OTk4cFBYbFEtLThfbXI5MGtzY3BIZWlaaGZBS29Sa01RVFRWN1pwZGk1eVl3UThPT0trWDItMGctRVZ4UHZOdUtwQjhBNzNEWXJzcVJrZjhuUmEyWTdfUUlzMXZQdkQyMG1iaU51Uml6RnRmcVptLV9IdEZWekJzOF9pQkFyYmdyU0kzNkVjTm5EcWJyMGV2bVFfdDhOY0lPdG1FZEZfNjN5ZFJ2bFlNOS1wS2R3MHZsUQ?oc=5", "tier": "direct", "title": "Freenome, Inc. (FRNM) CFO discloses initial share and stock option positions", "topics": [], "summary": "", "age_days": 19.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNdFNpVzZ0dC1yM2o3UjljSUo2OTk4cFBYbFEtLThfbXI5MGtzY3BIZWlaaGZBS29Sa01RVFRWN1pwZGk1eVl3UThPT0trWDItMGctRVZ4UHZOdUtwQjhBNzNEWXJzcVJrZjhuUmEyWTdfUUlzMXZQdkQyMG1iaU51Uml6RnRmcVptLV9IdEZWekJzOF9pQkFyYmdyU0kzNkVjTm5EcWJyMGV2bVFfdDhOY0lPdG1FZEZfNjN5ZFJ2bFlNOS1wS2R3MHZsUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 5.9e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.biospace.com/press-releases/fda-approves-freenomes-simplescreen-crc-blood-based-screening-test-abbott-to-commercialize-in-the-u-s", "tier": "direct", "title": "FDA Approves Freenome\u2019s SimpleScreen\u2122 CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.", "topics": ["Life Sciences"], "summary": "The FDA has approved Freenome's SimpleScreen\u2122 CRC, a blood-based screening test for colorectal cancer, which Abbott will commercialize in the U.S. this fall. This approval provides a new, convenient screening option for adults aged 45 and older at average risk for CRC, a disease that remains highly preventable with early detection. The test demonstrated 81.1% sensitivity for detecting colorectal cancer in a large clinical trial and is expected to expand access to screening, supported by Medicare coverage and anticipated American Cancer Society guidelines.", "age_days": 20.5, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/fda-approves-freenomes-simplescreen-crc-blood-based-screening-test-abbott-to-commercialize-in-the-u-s", "source_name": "BioSpace", "published_at": "2026-07-26T09:11:11", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 0.1, "sentiment_pct": 70, "evidence_basis": "archived_article", "evidence_share": 0.6, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000104, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 40, "published_display": "26 Jul 2026 09:11", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0.6"}, {"url": "https://www.tradingview.com/symbols/NASDAQ-FRNM/financials-statistics-and-ratios/operating-cash-flow-per-share", "tier": "direct", "title": "Operating cash flow per share of Freenome, Inc. \u2013 NASDAQ:FRNM", "topics": ["Earnings", "Life Sciences"], "summary": "This article focuses on the operating cash flow per share of Freenome, Inc. (NASDAQ: FRNM). It appears to be a financial data page from TradingView, providing financial metrics for the biotechnology company. The page indicates market status and provides navigation to other financial details.", "age_days": 23.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/symbols/NASDAQ-FRNM/financials-statistics-and-ratios/operating-cash-flow-per-share", "source_name": "TradingView", "published_at": "2026-07-23T22:09:49", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 4.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.003957, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Jul 2026 22:09", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.globenewswire.com/news-release/2026/07/20/3330086/0/en/freenome-debuts-as-a-publicly-traded-company-focused-on-blood-based-early-cancer-detection.html", "tier": "direct", "title": "Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection", "topics": ["IPO", "Life Sciences"], "summary": "Freenome, an early cancer detection company, has become publicly traded on the Nasdaq Capital Market under the ticker \"FRNM\" after completing its business combination with Perceptive Capital Solutions Corp. The company raised over $300 million in gross proceeds, which will fund the expansion of its cancer screening portfolio, AI/ML-enabled multiomics platform, and commercial infrastructure. Freenome aims to make early cancer detection simple, accessible, and personalized, focusing on blood-based tests for various cancer types, starting with colorectal cancer.", "age_days": 26.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3330086/0/en/freenome-debuts-as-a-publicly-traded-company-focused-on-blood-based-early-cancer-detection.html", "source_name": "GlobeNewswire", "published_at": "2026-07-20T16:01:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 6e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "20 Jul 2026 16:01", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://www.marketbeat.com/stocks/NASDAQ/FRNM/sec-filings", "tier": "direct", "title": "Freenome (FRNM) 10K Form and Latest SEC Filings 2026", "topics": ["Earnings", "Finance", "Financial Markets"], "summary": "This article provides an overview of Freenome's (FRNM) SEC filings, highlighting that the company has submitted over 82 documents since 2024. It details various filing types like 10-K, 10-Q, 8-K, and Form 4, explaining their significance for investors. The most recent filing mentioned is a Form SCHEDULE 13G/A submitted on August 14, 2026.", "age_days": 0.3, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "59e67dfb7d0a4bde206770a0107f85701789cd23c4fcaa405df75b757e333712", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/stocks/NASDAQ/FRNM/sec-filings", "source_name": "MarketBeat", "published_at": "2026-08-15T14:10:13", "source_names": ["MarketBeat"], "target_scope": "Freenome (FRNM) 10K Form and Latest SEC Filings 2026 This article provides an overview of Freenome's (FRNM) SEC filings, highlighting that the company has submitted over 82 documents since 2024.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 95.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.091625, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["FRNM"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "15 Aug 2026 14:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.0145}, {"url": "https://www.stocktitan.net/sec-filings/FRNM/8-k-a-freenome-inc-amends-material-event-report-c407cead4760.html", "tier": "direct", "title": "Freenome (FRNM) posts $132.6M loss but raises $295.5M via SPAC and PIPE", "topics": ["Earnings", "Finance", "IPO", "Life Sciences", "Mergers And Acquisitions"], "summary": "Freenome Inc. reported a net loss of $132.6 million for the first half of 2026, widening from the previous year, and used $97.1 million in operating cash. Despite these losses and an accumulated deficit of $1.5 billion, the company secured $295.5 million in net proceeds from a SPAC business combination and PIPE financing. This capital, along with existing liquidity, is expected to fund operations for at least 12 months, supporting ongoing R&D and commercialization efforts, especially after the recent FDA approval of its SimpleScreen\u2122 CRC test.", "age_days": 2.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "43dcb59852267ae3fa05f5abd36d3605432e3996b7b9efe8f6750d66115f0651", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/FRNM/8-k-a-freenome-inc-amends-material-event-report-c407cead4760.html", "source_name": "Stock Titan", "published_at": "2026-08-13T21:41:10", "source_names": ["Stock Titan"], "target_scope": "Freenome (FRNM) posts $132.6M loss but raises $295.5M via SPAC and PIPE Freenome Inc.", "tone_signals": ["Fda Approval"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 81.8, "sentiment_pct": 53, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.073973, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 93, "model_confidence": 0.501, "provider_symbols": ["ABT", "FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "13 Aug 2026 21:41", "direction_included": false, "sentiment_conflict": 0.68, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.2211}, {"url": "https://ca.investing.com/news/stock-market-news/form-8k-freenome-inc-for-13-august-93CH-4799859", "tier": "direct", "title": "Form 8K Freenome Inc For: 13 August By Investing.com", "topics": ["Earnings", "Financial Markets"], "summary": "This article from Investing.com announces that Freenome Inc. filed a Form 8K for August 13. The content of the filing itself is not detailed, as the article primarily serves as a notification of the filing. It mentions the stock symbol FRNM and provides general market data and other news.", "age_days": 2.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "5cd68aac41809ec7dcd1075dd2fab8d5c9861923163bed2ef655c846d196b76e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://ca.investing.com/news/stock-market-news/form-8k-freenome-inc-for-13-august-93CH-4799859", "source_name": "Investing.com Canada", "published_at": "2026-08-13T21:38:49", "source_names": ["Investing.com Canada"], "target_scope": "Form 8K Freenome Inc For: 13 August By Investing.com This article from Investing.com announces that Freenome Inc. It mentions the stock symbol FRNM and provides general market data and other news.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 75.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.099088, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 21:38", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.0203}, {"url": "https://www.stocktitan.net/news/FRNM/fda-grants-breakthrough-device-designation-to-freenome-s-blood-based-2jjlbqwwrcx6.html", "tier": "direct", "title": "Freenome targets lung screening gap; only about 18% of U.S. adults recommended get screened", "topics": ["Earnings", "Life Sciences", "Technology"], "summary": "Freenome has received FDA Breakthrough Device Designation for its investigational SimpleScreen\u2122 Lung test, a blood-based screening tool for lung cancer. The test is designed for high-risk adults aged 50-80 with a significant smoking history who are not currently undergoing recommended screening, aiming to address the substantial screening gap where only about 18% of eligible U.S. adults get screened. While the designation accelerates the review process and is a positive step, the market reacted with a slight decline in FRNM stock, as the test remains investigational and not yet FDA approved for routine use.", "age_days": 3.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "2548a77ec805a2d9e86123423570e3db03abcc51e8c3d9d8f9775ee8dd994676", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/news/FRNM/fda-grants-breakthrough-device-designation-to-freenome-s-blood-based-2jjlbqwwrcx6.html", "source_name": "Stock Titan", "published_at": "2026-08-12T13:40:37", "source_names": ["Stock Titan"], "target_scope": "Freenome targets lung screening gap Freenome has received FDA Breakthrough Device Designation for its investigational SimpleScreen\u2122 Lung test, a blood-based screening tool for lung cancer. While the designation accelerates the review process and is a positive step, the market reacted with a slight decline in FRNM stock, as the test remains investigational and not yet FDA approved for routine use.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 71.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.071757, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.423, "provider_symbols": ["FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 13:40", "direction_included": false, "sentiment_conflict": 0.244, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.0058}, {"url": "https://au.finance.yahoo.com/quote/FRNM/sec-filing", "tier": "direct", "title": "Freenome, Inc. (FRNM) stock price, news, quote and history", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "This article provides an overview of Freenome, Inc. (FRNM) stock performance, including its current price, news, and historical data. It details the company's stock price movement, key financial metrics like trailing total returns against the S&P 500, and lists relevant market data. The content also includes a snapshot of market activity for various indices and commodities.", "age_days": 7.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "7ee0f7f701c185efd9f5fab047c36b78af49e8738ba6311832d0809a51c251cb", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://au.finance.yahoo.com/quote/FRNM/sec-filing", "source_name": "Market source", "published_at": "2026-08-08T05:10:58", "source_names": ["Market source"], "target_scope": "Freenome, Inc. (FRNM) stock price, news, quote and history This article provides an overview of Freenome, Inc. (FRNM) stock performance, including its current price, news, and historical data. It details the company's stock price movement, key financial metrics like trailing total returns against the S&P 500, and lists relevant market data.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 34.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.025895, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Aug 2026 05:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.0139}, {"url": "https://www.reveliolabs.com/companies/freenome-holdings/employees", "tier": "direct", "title": "Freenome Holdings Number of Employees 2026 | Employee Count & Headcount Data", "topics": ["Finance", "Life Sciences"], "summary": "Freenome Holdings, a Biotech and Healthcare Services company founded in 2014 and headquartered in Brisbane, California, had approximately 527 employees worldwide as of March 2026. This represents a 26.8% decline from 719 employees in 2023, though the company saw a slight increase from a low of 519 in Q4 2025. The workforce is concentrated in the United States (74.8%), with an average salary of $149,649, and the company is actively hiring with 42 job postings in 2026.", "age_days": 13.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "be42ecd45f450b63925a62de797325e689771775ff588647fd6b4da18a018d19", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.reveliolabs.com/companies/freenome-holdings/employees", "source_name": "Revelio Labs", "published_at": "2026-08-02T09:11:11", "source_names": ["Revelio Labs"], "target_scope": "Freenome Holdings Number of Employees 2026 | Employee Count & Headcount Data Freenome Holdings, a Biotech and Healthcare Services company founded in 2014 and headquartered in Brisbane, California, had approximately 527 employees worldwide as of March 2026.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000642, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.45, "provider_symbols": ["FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "02 Aug 2026 09:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.3299}, {"url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5JWm5ra05qZFc3R2kyVE13a1c0aWtWZ21lbVJIUWpHa1N4QkR2YVR4NGFkck5SU2FsZko2ODRxZmZlTTdleGRuWTZXb1FsZWxk?oc=5", "tier": "direct", "title": "FRNM | Freenome, Inc. Common stock Stock Data, Price & News", "topics": [], "summary": "", "age_days": 15.7, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "9651caf2fde9f21d13f99e134c33f6e54269a41650a5f687d1d7569fda64ba19", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE5JWm5ra05qZFc3R2kyVE13a1c0aWtWZ21lbVJIUWpHa1N4QkR2YVR4NGFkck5SU2FsZko2ODRxZmZlTTdleGRuWTZXb1FsZWxk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-31T04:37:39+00:00", "source_names": ["Quiver Quantitative"], "target_scope": "FRNM | Freenome, Inc. Common stock Stock Data, Price & News", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000229, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Jul 2026 04:37", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM.ARCHIVE", "provider_directional_mass": null}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-frnm/freenome/information", "tier": "direct", "title": "Freenome, Inc. (FRNM) Company Information", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences", "Technology"], "summary": "This article provides company information for Freenome, Inc. (FRNM), including its key details like ticker, exchange, founding year, industry, and market capitalization. It also outlines the data sources used for the company analysis, such as financial statements, analyst estimates, and market prices, and mentions that Freenome, Inc. is not covered by any analysts for revenue or earnings estimates.", "age_days": 18.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "5900f1dc0e279bcb33bfab403a5fe23a3316365f0970b81dd8ee0d4d62179e2f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-frnm/freenome/information", "source_name": "Simply Wall Street", "published_at": "2026-07-28T01:40:36", "source_names": ["Simply Wall Street"], "target_scope": "Freenome, Inc. (FRNM) Company Information This article provides company information for Freenome, Inc. (FRNM), including its key details like ticker, exchange, founding year, industry, and market capitalization. It also outlines the data sources used for the company analysis, such as financial statements, analyst estimates, and market prices, and mentions that Freenome, Inc.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.00703, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "28 Jul 2026 01:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.1136}, {"url": "https://finance.yahoo.com/healthcare/articles/freenome-secures-fda-nod-blood-153750014.html", "tier": "direct", "title": "Freenome secures FDA nod for blood-based colorectal cancer test", "topics": ["Life Sciences"], "summary": "Freenome has received FDA approval for its blood-based colorectal cancer screening test, SimpleScreen CRC. Abbott will exclusively market the test in the U.S., adding it to its existing portfolio which includes the Cologuard stool test. The test is approved for adults 45 and older at average risk for colorectal cancer and aims to address the significant number of unscreened individuals.", "age_days": 19.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "6d29087f9ae8fbbc610e05bd7f44b66c6596b3767c3bb6952b7102e36b536bf2", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/freenome-secures-fda-nod-blood-153750014.html", "source_name": "Market source", "published_at": "2026-07-27T11:41:10", "source_names": ["Market source"], "target_scope": "Freenome secures FDA nod for blood-based colorectal cancer test Freenome has received FDA approval for its blood-based colorectal cancer screening test, SimpleScreen CRC.", "tone_signals": ["Fda Approval"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 14.6, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 99.4, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.018151, "influence_label": "Low", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.536, "provider_symbols": ["ABT", "DGX", "FRNM", "FRNM.ARCHIVE", "QCOM"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 34, "published_display": "27 Jul 2026 11:41", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "99.4", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.4325}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPWmJiLXVWQkhtMFF3OThrd2hpcTN1dVRjbEF0aW5GdE5XblpUeEFnZ3lOc1gyaGUycEJha1pDeVpsSFNycEM0NGZUcmpzOHpGYjRLeC01alJHWV9vRUtraVFDNFprcElIdVVYNU9PbWpNSmMzVFd4cTVSNWxOV09rc3AzM0hhdm9DZ013Ym5RdE94T2FHeFJWWFQ2VERCT0I5UUlGSWJ3X2R0cllLbXNGQ0RVMExIUFNnTXVFQWpFdDNmbkJhTDltODJSYw?oc=5", "tier": "direct", "title": "Freenome, Inc. (PCSC) CPO details common stock and multiple option grants", "topics": [], "summary": "", "age_days": 19.6, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "d0b3c031f489ff71d66ab2e554e1e71d22d08c42016c7e539333cd3628b1fdb3", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPWmJiLXVWQkhtMFF3OThrd2hpcTN1dVRjbEF0aW5GdE5XblpUeEFnZ3lOc1gyaGUycEJha1pDeVpsSFNycEM0NGZUcmpzOHpGYjRLeC01alJHWV9vRUtraVFDNFprcElIdVVYNU9PbWpNSmMzVFd4cTVSNWxOV09rc3AzM0hhdm9DZ013Ym5RdE94T2FHeFJWWFQ2VERCT0I5UUlGSWJ3X2R0cllLbXNGQ0RVMExIUFNnTXVFQWpFdDNmbkJhTDltODJSYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Freenome, Inc. (PCSC) CPO details common stock and multiple option grants", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 5.9e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNOWZzSHJvQkZYZkt0aGEzek1sWkQwUmp0UUJjeS1HaDF4WHJtakVVMlFPZm0wUXhXTkt1Rnhjd0hVSndERjNzWWh0NXJfcVZsemhZLXNxMWJFa0tEVmNjUkRJRkMyYlpSMXdQQWZzQUF4Z1dEM19OZTBiazFtUHg2SlpVNHpQY3RudE5iUngyazd3T3hybzloc1J0cUZmWEdmc0pSd3JSeURobjI5Y2pwZmstRHpTSXlCcW50N2dKZXEwSnE2cVJKLXZVUQ?oc=5", "tier": "direct", "title": "Freenome, Inc. (PCSC) director reports common stock and option stakes", "topics": [], "summary": "", "age_days": 19.6, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "2ce06a0b237ea17e301ba6e46cb04c0b75786b9a3c95c41e75a73d247b4f6ced", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNOWZzSHJvQkZYZkt0aGEzek1sWkQwUmp0UUJjeS1HaDF4WHJtakVVMlFPZm0wUXhXTkt1Rnhjd0hVSndERjNzWWh0NXJfcVZsemhZLXNxMWJFa0tEVmNjUkRJRkMyYlpSMXdQQWZzQUF4Z1dEM19OZTBiazFtUHg2SlpVNHpQY3RudE5iUngyazd3T3hybzloc1J0cUZmWEdmc0pSd3JSeURobjI5Y2pwZmstRHpTSXlCcW50N2dKZXEwSnE2cVJKLXZVUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Freenome, Inc. (PCSC) director reports common stock and option stakes", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 5.9e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNdFNpVzZ0dC1yM2o3UjljSUo2OTk4cFBYbFEtLThfbXI5MGtzY3BIZWlaaGZBS29Sa01RVFRWN1pwZGk1eVl3UThPT0trWDItMGctRVZ4UHZOdUtwQjhBNzNEWXJzcVJrZjhuUmEyWTdfUUlzMXZQdkQyMG1iaU51Uml6RnRmcVptLV9IdEZWekJzOF9pQkFyYmdyU0kzNkVjTm5EcWJyMGV2bVFfdDhOY0lPdG1FZEZfNjN5ZFJ2bFlNOS1wS2R3MHZsUQ?oc=5", "tier": "direct", "title": "Freenome, Inc. (FRNM) CFO discloses initial share and stock option positions", "topics": [], "summary": "", "age_days": 19.6, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "61e9fa7a4272d8224752723f846eeba602129e0649a4de362f639dde06a2cd3f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNdFNpVzZ0dC1yM2o3UjljSUo2OTk4cFBYbFEtLThfbXI5MGtzY3BIZWlaaGZBS29Sa01RVFRWN1pwZGk1eVl3UThPT0trWDItMGctRVZ4UHZOdUtwQjhBNzNEWXJzcVJrZjhuUmEyWTdfUUlzMXZQdkQyMG1iaU51Uml6RnRmcVptLV9IdEZWekJzOF9pQkFyYmdyU0kzNkVjTm5EcWJyMGV2bVFfdDhOY0lPdG1FZEZfNjN5ZFJ2bFlNOS1wS2R3MHZsUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Freenome, Inc. (FRNM) CFO discloses initial share and stock option positions", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 5.9e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.biospace.com/press-releases/fda-approves-freenomes-simplescreen-crc-blood-based-screening-test-abbott-to-commercialize-in-the-u-s", "tier": "direct", "title": "FDA Approves Freenome\u2019s SimpleScreen\u2122 CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.", "topics": ["Life Sciences"], "summary": "The FDA has approved Freenome's SimpleScreen\u2122 CRC, a blood-based screening test for colorectal cancer, which Abbott will commercialize in the U.S. this fall. This approval provides a new, convenient screening option for adults aged 45 and older at average risk for CRC, a disease that remains highly preventable with early detection. The test demonstrated 81.1% sensitivity for detecting colorectal cancer in a large clinical trial and is expected to expand access to screening, supported by Medicare coverage and anticipated American Cancer Society guidelines.", "age_days": 20.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "a6f2eb4e2e85f051c3906f51013c56ffc60a2726097ce9bc29714ebfb6d4fb85", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/fda-approves-freenomes-simplescreen-crc-blood-based-screening-test-abbott-to-commercialize-in-the-u-s", "source_name": "BioSpace", "published_at": "2026-07-26T09:11:11", "source_names": ["BioSpace"], "target_scope": "FDA Approves Freenome\u2019s SimpleScreen\u2122 CRC Blood-Based Screening Test The FDA has approved Freenome's SimpleScreen\u2122 CRC, a blood-based screening test for colorectal cancer, which Abbott will commercialize in the U.S.", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 70, "evidence_basis": "archived_article", "evidence_share": 0.6, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000104, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.67, "provider_symbols": ["ABT", "DGX", "FRNM", "FRNM.ARCHIVE", "LH"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 40, "published_display": "26 Jul 2026 09:11", "direction_included": true, "sentiment_conflict": 0.086, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0.6", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.4526}, {"url": "https://www.tradingview.com/symbols/NASDAQ-FRNM/financials-statistics-and-ratios/operating-cash-flow-per-share", "tier": "direct", "title": "Operating cash flow per share of Freenome, Inc. \u2013 NASDAQ:FRNM", "topics": ["Earnings", "Life Sciences"], "summary": "This article focuses on the operating cash flow per share of Freenome, Inc. (NASDAQ: FRNM). It appears to be a financial data page from TradingView, providing financial metrics for the biotechnology company. The page indicates market status and provides navigation to other financial details.", "age_days": 23.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "9efe8369904108346c42ab6b71be5d60412f84ed1baed6519f16ea36422983d2", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/symbols/NASDAQ-FRNM/financials-statistics-and-ratios/operating-cash-flow-per-share", "source_name": "TradingView", "published_at": "2026-07-23T22:09:49", "source_names": ["TradingView"], "target_scope": "Operating cash flow per share of Freenome, Inc. \u2013 NASDAQ:FRNM This article focuses on the operating cash flow per share of Freenome, Inc. (NASDAQ: FRNM).", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.003957, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["FRNM", "FRNM.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Jul 2026 22:09", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.0005}, {"url": "https://www.globenewswire.com/news-release/2026/07/20/3330086/0/en/freenome-debuts-as-a-publicly-traded-company-focused-on-blood-based-early-cancer-detection.html", "tier": "direct", "title": "Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection", "topics": ["IPO", "Life Sciences"], "summary": "Freenome, an early cancer detection company, has become publicly traded on the Nasdaq Capital Market under the ticker \"FRNM\" after completing its business combination with Perceptive Capital Solutions Corp. The company raised over $300 million in gross proceeds, which will fund the expansion of its cancer screening portfolio, AI/ML-enabled multiomics platform, and commercial infrastructure. Freenome aims to make early cancer detection simple, accessible, and personalized, focusing on blood-based tests for various cancer types, starting with colorectal cancer.", "age_days": 26.3, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "8d5bd8ffbbd73ac9c1998ea0b9e4bebea04c1dad709f8cb7ff5acf2717a9423f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/07/20/3330086/0/en/freenome-debuts-as-a-publicly-traded-company-focused-on-blood-based-early-cancer-detection.html", "source_name": "GlobeNewswire", "published_at": "2026-07-20T16:01:00", "source_names": ["GlobeNewswire"], "target_scope": "Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection Freenome, an early cancer detection company, has become publicly traded on the Nasdaq Capital Market under the ticker \"FRNM\" after completing its business combination with Perceptive Capital Solutions Corp. Freenome aims to make early cancer detection simple, accessible, and personalized, focusing on blood-based tests for various cancer types, starting with colorectal cancer.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 6e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["ABT", "FRNM", "FRNM.ARCHIVE", "MRNA"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "20 Jul 2026 16:01", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "FRNM", "provider_directional_mass": 0.8645}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 50, "display": "50", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 15, "display": "15", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 78, "display": "78%", "tone": "positive", "note": "15 company stories"}, {"label": "Story agreement", "value": 99, "display": "99", "tone": "positive", "note": "1/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 0, "note": "0.018 after freshness weighting"}, {"label": "Source breadth", "value": 40, "note": "2 independent publishers"}, {"label": "Company relevance", "value": 78, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 61, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 99, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 1, "note": "less reliance on one publisher"}], "freshness": 61, "source_independence": 1, "timeline": [{"date": "2026-07-18", "label": "18 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 1, "score": 70, "tone": "positive", "x": 294.7, "y": 98.6, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 4, "score": 57, "tone": "neutral", "x": 326.3, "y": 122.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 2, "score": 51, "tone": "neutral", "x": 863.2, "y": 133.2, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-15", "label": "15 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-16", "label": "16 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "105.2,135.0 199.9,135.0 294.7,98.6 326.3,122.3 357.9,135.0 452.6,135.0 515.8,135.0 705.3,135.0 831.7,135.0 863.2,133.2 926.4,135.0", "timeline_has_signal": true, "timeline_start": "18 Jul", "timeline_mid": "02 Aug", "timeline_end": "16 Aug", "momentum": {"label": "Stable but thin", "tone": "neutral", "recent_score": 51, "prior_score": 50, "delta": 1, "recent_count": 3, "prior_count": 1, "volume_delta": 2, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "New stories need a baseline", "tone": "neutral", "latest_score": 50, "baseline_score": 51, "delta": null, "latest_count": 1, "baseline_count": 3, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 1, "share": 7}, {"label": "1 to 3 days", "count": 2, "share": 13}, {"label": "4 to 7 days", "count": 1, "share": 7}, {"label": "8 to 14 days", "count": 2, "share": 13}, {"label": "15 to 21 days", "count": 7, "share": 47}, {"label": "22 to 30 days", "count": 2, "share": 13}], "source_profile": [{"label": "Stock Titan", "count": 5, "share": 33, "score": 52, "tone": "neutral"}, {"label": "Market source", "count": 2, "share": 13, "score": 53, "tone": "neutral"}, {"label": "BioSpace", "count": 1, "share": 7, "score": 70, "tone": "positive"}, {"label": "MarketBeat", "count": 1, "share": 7, "score": 50, "tone": "neutral"}, {"label": "Investing.com Canada", "count": 1, "share": 7, "score": 50, "tone": "neutral"}, {"label": "Revelio Labs", "count": 1, "share": 7, "score": 50, "tone": "neutral"}, {"label": "Quiver Quantitative", "count": 1, "share": 7, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 7, "share": 47, "score": 52, "tone": "neutral"}, {"label": "Earnings", "count": 5, "share": 33, "score": 50, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 2, "share": 13, "score": 51, "tone": "neutral"}, {"label": "Deals and strategy", "count": 1, "share": 7, "score": 53, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 9, "share": 60}, {"label": "Earnings", "count": 7, "share": 47}, {"label": "Finance", "count": 5, "share": 33}, {"label": "Financial Markets", "count": 4, "share": 27}, {"label": "Technology", "count": 2, "share": 13}, {"label": "IPO", "count": 2, "share": 13}, {"label": "Mergers And Acquisitions", "count": 1, "share": 7}], "supporting": [{"label": "Direct evidence", "text": "15 current stories are mapped specifically to FRNM."}], "tempering": [{"label": "Source breadth", "text": "Only 2 publishers currently contribute to the measured read."}, {"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.018."}, {"label": "Confidence", "text": "Confidence is 15/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://www.marketbeat.com/stocks/NASDAQ/FRNM/sec-filings", "tier": "direct", "title": "Freenome (FRNM) 10K Form and Latest SEC Filings 2026", "topics": ["Earnings", "Finance", "Financial Markets"], "summary": "This article provides an overview of Freenome's (FRNM) SEC filings, highlighting that the company has submitted over 82 documents since 2024. It details various filing types like 10-K, 10-Q, 8-K, and Form 4, explaining their significance for investors. The most recent filing mentioned is a Form SCHEDULE 13G/A submitted on August 14, 2026.", "age_days": 0.3, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/stocks/NASDAQ/FRNM/sec-filings", "source_name": "MarketBeat", "published_at": "2026-08-15T14:10:13", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 95.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.091625, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "15 Aug 2026 14:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 15, "updated_at": "2026-08-15T22:14:42.210291+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 154.6, "label": "24 Jul 2026", "close": 11.24, "index": 100.0}, {"x": 333.5, "y": 173.9, "label": "31 Jul 2026", "close": 11.15, "index": 99.2}, {"x": 624.9, "y": 173.9, "label": "07 Aug 2026", "close": 11.15, "index": 99.2}, {"x": 916.4, "y": 86.1, "label": "14 Aug 2026", "close": 11.56, "index": 102.8}], "sentiment_points": [{"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 11.24, "label": "24 Jul 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": null, "x": 83.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 11.15, "label": "31 Jul 2026", "score": 53, "stories": 9, "raw_score": 65, "confidence": 27, "price_change": -0.8, "x": 375.1, "y": 124.5, "show_label": true, "label_y": 114.5}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 11.15, "label": "07 Aug 2026", "score": 51, "stories": 10, "raw_score": 65, "confidence": 21, "price_change": 0.0, "x": 666.5, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 11.56, "label": "14 Aug 2026", "score": 53, "stories": 15, "raw_score": 67, "confidence": 27, "price_change": 3.7, "x": 958.0, "y": 124.5, "show_label": true, "label_y": 114.5}], "price_path": "42.0,154.6 333.5,173.9 624.9,173.9 916.4,86.1", "sentiment_path": "83.6,130.0 375.1,124.5 666.5,128.2 958.0,124.5", "score_version": "evidence-v10", "price_change": 2.8, "sentiment_change": 3, "recent_pairs": [{"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 11.56, "label": "14 Aug 2026", "score": 53, "stories": 15, "raw_score": 67, "confidence": 27, "price_change": 3.7, "x": 958.0, "y": 124.5, "show_label": true, "label_y": 114.5}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 11.15, "label": "07 Aug 2026", "score": 51, "stories": 10, "raw_score": 65, "confidence": 21, "price_change": 0.0, "x": 666.5, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 11.15, "label": "31 Jul 2026", "score": 53, "stories": 9, "raw_score": 65, "confidence": 27, "price_change": -0.8, "x": 375.1, "y": 124.5, "show_label": true, "label_y": 114.5}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 11.24, "label": "24 Jul 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": null, "x": 83.6, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 11.56, "start_label": "24 Jul", "mid_label": "07 Aug", "end_label": "14 Aug", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"tone": "neutral", "delta": 4, "label": "26 Jul 23:59", "score": 54, "height": 8, "articles": 3, "confidence": 32, "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": null, "score_change_display": "Start"}, {"tone": "neutral", "delta": 4, "label": "27 Jul 23:59", "score": 54, "height": 8, "articles": 7, "confidence": 33, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 3, "label": "28 Jul 23:59", "score": 53, "height": 6, "articles": 8, "confidence": 31, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "31 Jul 23:59", "score": 53, "height": 6, "articles": 9, "confidence": 27, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "02 Aug 23:59", "score": 52, "height": 4, "articles": 10, "confidence": 25, "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 1, "label": "08 Aug 23:59", "score": 51, "height": 4, "articles": 11, "confidence": 20, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "12 Aug 23:59", "score": 53, "height": 6, "articles": 13, "confidence": 29, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+2"}, {"tone": "neutral", "delta": 3, "label": "13 Aug 23:59", "score": 53, "height": 6, "articles": 15, "confidence": 28, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 3, "label": "15 Aug 22:14", "score": 53, "height": 6, "articles": 16, "confidence": 26, "short_label": "15 Aug", "collected_at": "2026-08-15T22:14:42.195527+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 9, "span_label": "20 days", "first_score": 54, "latest_score": 53, "net_change": -1, "net_change_display": "-1", "direction": "Broadly stable", "high_score": 54, "low_score": 51, "latest_confidence": 26, "confidence_change": -6, "latest_articles": 16, "article_change": 13, "latest_label": "15 Aug 22:14", "latest_evidence_label": "Provisional", "chart_rows": [{"tone": "neutral", "delta": 4, "label": "26 Jul 23:59", "score": 54, "height": 8, "articles": 3, "confidence": 32, "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": null, "score_change_display": "Start", "x": 42.0, "y": 127.7}, {"tone": "neutral", "delta": 4, "label": "27 Jul 23:59", "score": 54, "height": 8, "articles": 7, "confidence": 33, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+0", "x": 156.5, "y": 127.7}, {"tone": "neutral", "delta": 3, "label": "28 Jul 23:59", "score": 53, "height": 6, "articles": 8, "confidence": 31, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1", "x": 271.0, "y": 129.5}, {"tone": "neutral", "delta": 3, "label": "31 Jul 23:59", "score": 53, "height": 6, "articles": 9, "confidence": 27, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0", "x": 385.5, "y": 129.5}, {"tone": "neutral", "delta": 2, "label": "02 Aug 23:59", "score": 52, "height": 4, "articles": 10, "confidence": 25, "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1", "x": 500.0, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "08 Aug 23:59", "score": 51, "height": 4, "articles": 11, "confidence": 20, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1", "x": 614.5, "y": 133.2}, {"tone": "neutral", "delta": 3, "label": "12 Aug 23:59", "score": 53, "height": 6, "articles": 13, "confidence": 29, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+2", "x": 729.0, "y": 129.5}, {"tone": "neutral", "delta": 3, "label": "13 Aug 23:59", "score": 53, "height": 6, "articles": 15, "confidence": 28, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 843.5, "y": 129.5}, {"tone": "neutral", "delta": 3, "label": "15 Aug 22:14", "score": 53, "height": 6, "articles": 16, "confidence": 26, "short_label": "15 Aug", "collected_at": "2026-08-15T22:14:42.195527+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 958.0, "y": 129.5}], "chart_points": "42.0,127.7 156.5,127.7 271.0,129.5 385.5,129.5 500.0,131.4 614.5,133.2 729.0,129.5 843.5,129.5 958.0,129.5", "changes": [{"tone": "neutral", "delta": 3, "label": "15 Aug 22:14", "score": 53, "height": 6, "articles": 16, "confidence": 26, "short_label": "15 Aug", "collected_at": "2026-08-15T22:14:42.195527+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 3, "label": "13 Aug 23:59", "score": 53, "height": 6, "articles": 15, "confidence": 28, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 3, "label": "12 Aug 23:59", "score": 53, "height": 6, "articles": 13, "confidence": 29, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+2"}, {"tone": "neutral", "delta": 1, "label": "08 Aug 23:59", "score": 51, "height": 4, "articles": 11, "confidence": 20, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "02 Aug 23:59", "score": 52, "height": 4, "articles": 10, "confidence": 25, "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "31 Jul 23:59", "score": 53, "height": 6, "articles": 9, "confidence": 27, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0"}, {"tone": "neutral", "delta": 3, "label": "28 Jul 23:59", "score": 53, "height": 6, "articles": 8, "confidence": 31, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 4, "label": "27 Jul 23:59", "score": 54, "height": 8, "articles": 7, "confidence": 33, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+0"}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}